Actualités et vidéos - CROSSJECT - Anglais

Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025. Recruitment of Tony Tipton as Chief Operating Officer USA. Visibility gained on pipeline programs developed in collaboration with Eton Pharmaceuticals, Inc (Eton). Cash position increasing significantly to 7 million euros as of December 31, 2024. Dijon, France, March 27, 2025 (07.30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ) a...

Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON’s net sales. ETON confirmed its commitment to finalize the development and...

Press Release CROSSJECT achieves key ZEPIZURE ® manufacturing batch stability milestones Satisfactory 6-month room temperature stability results for the Registration Batch of ZEPIZURE®; CDMO Partner EUROFINS in the process of producing additional validation batches as part of regulatory application; Manufacturing progress supports timelines toward filing of Emergency Use Authorization application by BARDA. Dijon, France March 18, 2025 CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty...

Dijon, FRANCE, February 12, 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces that, as of February 17, its Executive Board will be made up of Patrick Alexandre, Chairman, and Isabelle Liebschutz, Quality and Regulatory Affairs Director and the Company’s qualified person....

Press Release Dijon, FRANCE, February 6, 2025 –0730h (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces, in accordance with the agreement entered into with Heights in December 2024, the completion of the amendments of the terms and conditions of the bonds issued to an entity affiliated to...

Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France) Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company preparing to commercialize its epilepsy rescue therapy ZEPIZURE®, has successfully concluded a surveillance audit of its manufacturing sites, delivering new evidence its supply chain is ready to move ZEPIZURE®...

Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025 Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafter Crossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, France, October 22 2024 (07:30 CET) - Crossject...

Dijon, France, 17 September, 2024 - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, will report its financial results for the six months ended June 30, 2024, as scheduled on Monday, September 23. In addition, at 18:00 CET that day, CEO Patrick Alexandre will provide a commentary on the company’s strategic priorities during a webcast and be available for...

Dijon, France, July 15 th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE® , its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024. About Crossject Crossject SA (Euronext: ALCJ;...

Key contribution to the acceleration of the development of ZENEO® Epinephrine Financial support includes mainly grants, as well as subsidized loans France 2030 Plan dedicated to supporting French companies demonstrating outstanding growth and innovation potential Dijon, France, July 10 th , 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE® , its emergency treatment for the management of...

Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical products Reinforces leadership team and expands presence in North America Supports processes targeting ZEPIZURE® regulatory milestones in the U.S. in 2025 Dijon, France 12 June 2024 , 7:30 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE® , its emergency treatment for the management of...

Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April 2024 Allows to continue the clinical and regulatory development of ZEPIZURE® until the next value creation milestones, in particular the EUA approval by the FDA Dijon, France 4 April, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces the successful closing of its...

Dijon, France April 2, 2024 – Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject’s press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations. For that reason, Crossject required Euronext to stop trading. Following Euronext’s standard procedure in...

Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDA Expectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025 Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025 Reinforcement of supply chain [with addition of a second fill-and-finish CDMO] Reporting of a reduced Net loss of €8.5 million versus €11.2 million in 2022 Dijon, France April 2, 2024, 10:30am CET --...

Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%. The Gender Equality Index is a tool to measure the progress of gender equality in the EU, giving more visibility to areas that need improvement and ultimately supporting policy...

Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches, from an entity managed by Heights Capital Management, in issued bonds convertible in new shares, with a conversion premium of 35% 1 , or repayable (in cash and/or stocks, according to the company’s options) over 36 months at a rate of 7% 2 . CROSSJECT (ISIN: FR0011716265; Stock symbol: ALCJ) , a specialty pharma company developing needle-free auto-injectors for emergency situations, ,...

Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a conference call on its commercial strategy in the U.S. and Europe on February 6, 2024 at 17:30 CET. The presentation will be held in English. Patrick Alexandre, Crossject’s CEO and Executive Chairman, and Olivier Gire, COO of Specialty Pharma, will provide a business update following the January 4...

Press Release Crossject to present at Biotech Showcase on January 9 at 16:30 PT Dijon, France, January 9, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a presentation at the Biotech Showcase conference, being held in San Francisco, on January 9, 2024 at 16:30 PT (January 10, 01:30 CET). Details of the presentation: Time: Tuesday, January 9, 2024, 16:30 PT Track: Yosemite C (Ballroom...

Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE ®  Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE ® , previously known as ZENEO ® Midazolam, is separately contracted with BARDA for U.S. advanced regulatory development and specific supply to the Strategic National Stockpile Dijon, France, January 4, 2024, 18:00 CET -- Crossject (ISIN: FR0011716265; uronext: ALCJ), a specialty pharma company...

Crossject to receive up to €1 million on marketing approvals, plus a markup on sales linked to gross margin Agreement, with undisclosed strategic partner, allows Crossject to benefit from strong expertise in the field and provides impetus to commercial launches Dijon, France 22 December, 2023, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has concluded a commercialization...